Figure 2: Responses to the treatment at 48 weeks, characterized by clinical asthma symptoms (C-ACT points/week). Responses to the treatment are shown as follows: very good (>75% reduction), good (50 to 75% reduction), moderate (25 to 50% reduction) and poor (<25% reduction) [LTRA only (a) vs LTRA+ (b); with carbocystein and lysozyme chloride / ambroxol).